November 24, 2020

The Niche

Knoepfler lab stem cell blog

John Rasko of the University of Sydney

3 min read

Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, which looks to be a dramatic year in the field of stem cells and regenerative medicine. The Score Card on 2016 Predictions Another stem cell biotech acquisition by pharma …Read More

3 min read

The FDA is holding its first 2016 stem cell meeting today and you can read about some impressions of the morning session of this meeting here. In this post, I’m focusing on the afternoon session, which has been mostly on policy and ethics, including on stem cell clinics. Jonathan Kimmelman from McGill University got the afternoon going with his excellent talk “Ethics, Evidence, and Regulatory Approval for Cell-Based Interventions“. Jonathan started his talk addressing the stem cell clinic situation in the U.S. and asking more broadly how …Read More

2 min read

Last week a team led by John Rasko of the University of Sydney published a very important stem cell clinic study also in Cell Stem Cell. Thus, there have now been two new reports on the state of the stem cell clinic industry both here in the U.S. and more globally. Leigh Turner and I published our paper at the end of June on the American clinic industry, finding 351 businesses and 570 clinics selling non-FDA approved stem cell therapies. Rasko and colleagues did a much …Read More